Norway · Delayed Price · Currency is NOK Navamedic ASA Statistics
Total Valuation
Navamedic ASA has a market cap or net worth of NOK 254.20 million. The enterprise value is 388.45 million.
| Market Cap | 254.20M |
| Enterprise Value | 388.45M |
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Navamedic ASA has 23.98 million shares outstanding. The number of shares has increased by 34.92% in one year.
| Current Share Class | 23.98M |
| Shares Outstanding | 23.98M |
| Shares Change (YoY) | +34.92% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 11.51% |
| Owned by Institutions (%) | 13.15% |
| Float | 9.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.19 |
| PS Ratio | 0.46 |
| PB Ratio | 0.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.79 |
| P/OCF Ratio | 10.81 |
| PEG Ratio | 0.86 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.36, with an EV/FCF ratio of 18.02.
| EV / Earnings | n/a |
| EV / Sales | 0.70 |
| EV / EBITDA | 8.36 |
| EV / EBIT | n/a |
| EV / FCF | 18.02 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.45 |
| Quick Ratio | 0.75 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | 8.48 |
| Interest Coverage | -0.07 |
Financial Efficiency
Return on equity (ROE) is -10.02% and return on invested capital (ROIC) is -0.26%.
| Return on Equity (ROE) | -10.02% |
| Return on Assets (ROA) | -0.11% |
| Return on Invested Capital (ROIC) | -0.26% |
| Return on Capital Employed (ROCE) | -0.23% |
| Weighted Average Cost of Capital (WACC) | 6.34% |
| Revenue Per Employee | 14.63M |
| Profits Per Employee | -656,526 |
| Employee Count | 38 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 3.17 |
Taxes
In the past 12 months, Navamedic ASA has paid 1.65 million in taxes.
| Income Tax | 1.65M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.28% in the last 52 weeks. The beta is 0.25, so Navamedic ASA's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -49.28% |
| 50-Day Moving Average | 13.14 |
| 200-Day Moving Average | 17.32 |
| Relative Strength Index (RSI) | 30.22 |
| Average Volume (20 Days) | 92,904 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Navamedic ASA had revenue of NOK 556.03 million and -24.95 million in losses. Loss per share was -1.05.
| Revenue | 556.03M |
| Gross Profit | 216.45M |
| Operating Income | -1.12M |
| Pretax Income | -23.30M |
| Net Income | -24.95M |
| EBITDA | 43.45M |
| EBIT | -1.12M |
| Loss Per Share | -1.05 |
Balance Sheet
The company has 48.64 million in cash and 182.89 million in debt, with a net cash position of -134.25 million or -5.60 per share.
| Cash & Cash Equivalents | 48.64M |
| Total Debt | 182.89M |
| Net Cash | -134.25M |
| Net Cash Per Share | -5.60 |
| Equity (Book Value) | 288.21M |
| Book Value Per Share | 12.01 |
| Working Capital | 64.09M |
Cash Flow
In the last 12 months, operating cash flow was 23.52 million and capital expenditures -1.97 million, giving a free cash flow of 21.56 million.
| Operating Cash Flow | 23.52M |
| Capital Expenditures | -1.97M |
| Depreciation & Amortization | 44.57M |
| Net Borrowing | -140.09M |
| Free Cash Flow | 21.56M |
| FCF Per Share | 0.90 |
Margins
Gross margin is 38.93%, with operating and profit margins of -0.20% and -4.49%.
| Gross Margin | 38.93% |
| Operating Margin | -0.20% |
| Pretax Margin | -4.19% |
| Profit Margin | -4.49% |
| EBITDA Margin | 7.81% |
| EBIT Margin | -0.20% |
| FCF Margin | 3.88% |
Dividends & Yields
Navamedic ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -34.92% |
| Shareholder Yield | -34.92% |
| Earnings Yield | -9.89% |
| FCF Yield | 8.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Navamedic ASA is 20.97, which is 97.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 20.97 |
| Price Target Difference | 97.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 4.33% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Navamedic ASA has an Altman Z-Score of 1.75 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.75 |
| Piotroski F-Score | 4 |